Table Info

Table 1.

Adipokines and observations in PCOS

Adipokine	Action	Serum levels in PCOS	References
Adiponectin	Insulin sensitivity, inflammatory reaction, ovarian folliculogenesis	Decreased in PCOS	[164, 165, 167, 168]
Visfatin	Insulin mimetic action	Increased in PCOS	[169–171]
Resistin	Resist insulin action	Increased/unchanged in PCOS	[172–174]
Leptin	Regulatory role in body mass, food intake, reproductive function, pro-inflammatory immune reaction, and lipolysis	Increased/unchanged in PCOS	[176, 195]
Vaspin	Insulin sensitivity	Increased/decreased/unchanged in PCOS	[177–181]

Declarations

Author contributions

ML contributed conception and design of the study, reviewing and editing; BSJ wrote the first draft of the manuscript and analyzed the literature. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

ML is supported by Department of Biotechnology (DBT)-Rajiv Gandhi Centre for Biotechnology. BSJ is supported by a Senior Research Fellowship from ICMR [RBMH/FW/2020/2]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Witchel SF, Teede HJ, Peña AS. Curtailing PCOS. Pediatr Res. 2020;87:353–61. [DOI] [PubMed]

Crespo RP, Bachega TASS, Mendonça BB, Gomes LG. An update of genetic basis of PCOS pathogenesis. Arch Endocrinol Metab. 2018;62:352–61. [DOI] [PubMed]

Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–96. [DOI] [PubMed] [PMC]

Skiba MA, Islam RM, Bell RJ, Davis SR. Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018;24:694–709. [DOI] [PubMed]

Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017;8:96351–8. [DOI] [PubMed] [PMC]

Rao M, Broughton KS, LeMieux MJ. Cross-sectional study on the knowledge and prevalence of PCOS at a multiethnic university. PROGREVMED. 2020;5:e0028. [DOI]

Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014;29:791–801. [DOI] [PubMed]

Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13:261–71. [DOI] [PubMed] [PMC]

González DA, Díaz BB, Rodríguez Pérez Mdel C, Hernández AG, Chico BN, de León AC. Sex hormones and autoimmunity. Immunol Lett. 2010;133:6–13. [DOI] [PubMed]

10.

Bhatia A, Sekhon HK, Kaur G. Sex hormones and immune dimorphism. ScientificWorldJournal. 2014;2014:159150. [DOI] [PubMed] [PMC]

11.

Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411–23. [DOI] [PubMed]

12.

Taneja V. Sex hormones determine immune response. Front Immunol. 2018;9:1931. [DOI] [PubMed] [PMC]

13.

Ruggieri A, Anticoli S, D’Ambrosio A, Giordani L, Viora M. The influence of sex and gender on immunity, infection and vaccination. Ann Ist Super Sanita. 2016;52:198–204. [DOI] [PubMed]

14.

Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10:338–49. [DOI] [PubMed] [PMC]

15.

Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37:467–520. [DOI] [PubMed] [PMC]

16.

Ben-Batalla I, Vargas-Delgado ME, von Amsberg G, Janning M, Loges S. Influence of androgens on immunity to self and foreign: effects on immunity and cancer. Front Immunol. 2020;11:1184. [DOI] [PubMed] [PMC]

17.

Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem. 1991;266:510–8. [DOI] [PubMed]

18.

Matsumoto T, Sakari M, Okada M, Yokoyama A, Takahashi S, Kouzmenko A, et al. The androgen receptor in health and disease. Annu Rev Physiol. 2013;75:201–24. [DOI] [PubMed]

19.

Lai JJ, Lai KP, Zeng W, Chuang KH, Altuwaijri S, Chang C. Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice. Am J Pathol. 2012;181:1504–12. [DOI] [PubMed] [PMC]

20.

Olsen NJ, Olson G, Viselli SM, Gu X, Kovacs WJ. Androgen receptors in thymic epithelium modulate thymus size and thymocyte development. Endocrinology. 2001;142:1278–83. [DOI] [PubMed]

21.

Olsen NJ, Kovacs WJ. Evidence that androgens modulate human thymic T cell output. J Investig Med. 2011;59:32–5. [DOI] [PubMed] [PMC]

22.

Ellis TM, Moser MT, Le PT, Flanigan RC, Kwon ED. Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Int Immunol. 2001;13:553–8. [DOI] [PubMed]

23.

Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004;173:6098–108. [DOI] [PubMed]

24.

Liva SM, Voskuhl RR. Testosterone acts directly on CD4⁺ T lymphocytes to increase IL-10 production. J Immunol. 2001;167:2060–7. [DOI] [PubMed]

25.

Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci U S A. 2014;111:9887–92. [DOI] [PubMed] [PMC]

26.

Massa MG, David C, Jörg S, Berg J, Gisevius B, Hirschberg S, et al. Testosterone differentially affects T cells and neurons in murine and human models of neuroinflammation and neurodegeneration. Am J Pathol. 2017;187:1613–22. [DOI] [PubMed]

27.

Bao M, Yang Y, Jun HS, Yoon JW. Molecular mechanisms for gender differences in susceptibility to T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol. 2002;168:5369–75. [DOI] [PubMed]

28.

Wilcoxen SC, Kirkman E, Dowdell KC, Stohlman SA. Gender-dependent IL-12 secretion by APC is regulated by IL-10. J Immunol. 2000;164:6237–43. [DOI] [PubMed]

29.

Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006;1089:538–47. [DOI] [PubMed]

30.

Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol. 2006;176:2703–10. [DOI] [PubMed]

31.

Khan D, Ansar Ahmed S. The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. Front Immunol. 2016;6:635. [DOI] [PubMed] [PMC]

32.

Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. 2018;9:2279. [DOI] [PubMed] [PMC]

33.

Andersson A, Törnqvist AE, Moverare-Skrtic S, Bernardi AI, Farman HH, Chambon P, et al. Roles of activating functions 1 and 2 of estrogen receptor alpha in lymphopoiesis. J Endocrinol. 2018;236:99–109. [DOI] [PubMed]

34.

Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 2015;294:63–9. [DOI] [PubMed] [PMC]

35.

Karpuzoglu E, Ahmed SA. Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: implications for immunity, autoimmune diseases, and apoptosis. Nitric Oxide. 2006;15:177–86. [DOI] [PubMed]

36.

Liu HY, Buenafe AC, Matejuk A, Ito A, Zamora A, Dwyer J, et al. Estrogen inhibition of EAE involves effects on dendritic cell function. J Neurosci Res. 2002;70:238–48. [DOI] [PubMed]

37.

Cunningham MA, Wirth JR, Naga O, Eudaly J, Gilkeson GS. Estrogen receptor alpha binding to ERE is required for full Tlr7- and Tlr9-induced inflammation. SOJ Immunol. 2014;2:07. [DOI] [PubMed] [PMC]

38.

Seto K, Hoang M, Santos T, Bandyopadhyay M, Kindy MS, Dasgupta S. Non-genomic oestrogen receptor signal in B lymphocytes: an approach towards therapeutic interventions for infection, autoimmunity and cancer. Int J Biochem Cell Biol. 2016;76:115–8. [DOI] [PubMed]

39.

Bouman A, Schipper M, Heineman MJ, Faas MM. Gender difference in the non-specific and specific immune response in humans. Am J Reprod Immunol. 2004;52:19–26. [DOI] [PubMed]

40.

Lee BW, Yap HK, Chew FT, Quah TC, Prabhakaran K, Chan GS, et al. Age- and sex-related changes in lymphocyte subpopulations of healthy Asian subjects: from birth to adulthood. Cytometry. 1996;26:8–15. [DOI] [PubMed]

41.

Posma E, Moes H, Heineman MJ, Faas MM. The effect of testosterone on cytokine production in the specific and non-specific immune response. Am J Reprod Immunol. 2004;52:237–43. [DOI] [PubMed]

42.

Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol. 1997;159:3–6. [PubMed]

43.

Møller AP, Sorci G, Erritzøe J. Sexual dimorphism in immune defense. Am Nat. 1998;152:605–19. [DOI] [PubMed]

44.

Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. Neurosci Biobehav Rev. 2000;24:627–38. [DOI] [PubMed]

45.

Zuk M, McKean KA. Sex differences in parasite infections: patterns and processes. Int J Parasitol. 1996;26:1009–24. [DOI] [PubMed]

46.

Bwire GM. Coronavirus: why men are more vulnerable to covid-19 than women? SN Compr Clin Med. 2020;2:874–6. [DOI] [PubMed] [PMC]

47.

Chanana N, Palmo T, Sharma K, Kumar R, Graham BB, Pasha Q. Sex-derived attributes contributing to SARS-CoV-2 mortality. Am J Physiol Endocrinol Metab. 2020;319:E562–7. [DOI] [PubMed] [PMC]

48.

Naimi WA, Green RS, Cockburn CL, Carlyon JA. Differential susceptibility of male versus female laboratory mice to Anaplasma phagocytophilum infection. Trop Med Infect Dis. 2018;3:78. [DOI] [PubMed] [PMC]

49.

Alley J, Khasabov S, Simone D, Beitz A, Rodriguez M, Njenga MK. More severe neurologic deficits in SJL/J male than female mice following Theiler’s virus-induced CNS demyelination. Exp Neurol. 2003;180:14–24. [DOI] [PubMed]

50.

Marriott I, Huet-Hudson YM. Sexual dimorphism in innate immune responses to infectious organisms. Immunol Res. 2006;34:177–92. [DOI] [PubMed]

51.

Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38. [DOI] [PubMed]

52.

Abdullah M, Chai PS, Chong MY, Tohit ER, Ramasamy R, Pei CP, et al. Gender effect on in vitro lymphocyte subset levels of healthy individuals. Cell Immunol. 2012;272:214–9. [DOI] [PubMed]

53.

Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiébaut R, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A. 2014;111:869–74. [DOI] [PubMed] [PMC]

54.

Weinstein Y, Ran S, Segal S. Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J Immunol. 1984;132:656–61. [PubMed]

55.

Marriott I, Bost KL, Huet-Hudson YM. Sexual dimorphism in expression of receptors for bacterial lipopolysaccharides in murine macrophages: a possible mechanism for gender-based differences in endotoxic shock susceptibility. J Reprod Immunol. 2006;71:12–27. [DOI] [PubMed]

56.

Rowe PJ, Comhaire FH, Hargreave TB, Mellows HJ, editors. WHO manual for the standardized investigation and diagnosis of the infertile couple [Internet]. Cambridge: Cambridge University Press; 1993 [cited 2022 Mar 02]. Available from: https://www.who.int/publications/i/item/9780521431361

57.

Haller-Kikkatalo K, Salumets A, Uibo R. Review on autoimmune reactions in female infertility: antibodies to follicle stimulating hormone. Clin Dev Immunol. 2012;2012:762541. [DOI] [PubMed] [PMC]

58.

Gleicher N. Antiphospholipid antibodies (aPL) affect in vitro fertilization (IVF) outcome. Am J Reprod Immunol. 2001;46:330–1. [DOI] [PubMed]

59.

Komorowska B. Autoimmune premature ovarian failure. Prz Menopauzalny. 2016;15:210–4. [DOI] [PubMed] [PMC]

60.

Dragojević-Dikić S, Marisavljević D, Mitrović A, Dikić S, Jovanović T, Janković-Raznatović S. An immunological insight into premature ovarian failure (POF). Autoimmun Rev. 2010;9:771–4. [DOI] [PubMed]

61.

Ozkan ZS, Deveci D, Kumbak B, Simsek M, Ilhan F, Sekercioglu S, et al. What is the impact of Th1/Th2 ratio, SOCS3, IL17, and IL35 levels in unexplained infertility? J Reprod Immunol. 2014;103:53–8. [DOI] [PubMed]

62.

Barbarino-Monnier P, Gobert B, Guillet-Rosso F, Béné MC, Landes P, Faure G. Antiovary antibodies, repeated attempts, and outcome of in vitro fertilization. Fertil Steril. 1991;56:928–32. [DOI] [PubMed]

63.

Geva E, Lessing JB, Lerner-Geva L, Azem F, Yovel I, Amit A. The presence of antithyroid antibodies in euthyroid patients with unexplained infertility and tubal obstruction. Am J Reprod Immunol. 1997;37:184–6. [DOI] [PubMed]

64.

Deroux A, Dumestre-Perard C, Dunand-Faure C, Bouillet L, Hoffmann P. Female infertility and serum auto-antibodies: a systematic review. Clin Rev Allergy Immunol. 2017;53:78–86. [DOI] [PubMed]

65.

An LF, Zhang XH, Sun XT, Zhao LH, Li S, Wang WH. Unexplained infertility patients have increased serum IL-2, IL-4, IL-6, IL-8, IL-21, TNFalpha, IFNgamma and increased Tfh/CD4 T cell ratio: increased Tfh and IL-21 strongly correlate with presence of autoantibodies. Immunol Invest. 2015;44:164–73. [DOI] [PubMed]

66.

Yamamoto H, Yamashita Y, Saito N, Hayashi A, Hayashi M, Terai Y, et al. Lower FOXO3 mRNA expression in granulosa cells is involved in unexplained infertility. J Obstet Gynaecol Res. 2017;43:1021–8. [DOI] [PubMed]

67.

Jasper MJ, Tremellen KP, Robertson SA. Primary unexplained infertility is associated with reduced expression of the T-regulatory cell transcription factor Foxp3 in endometrial tissue. Mol Hum Reprod. 2006;12:301–8. [DOI] [PubMed]

68.

Tomassetti C, Meuleman C, Pexsters A, Mihalyi A, Kyama C, Simsa P, et al. Endometriosis, recurrent miscarriage and implantation failure: is there an immunological link? Reprod Biomed Online. 2006;13:58–64. [DOI] [PubMed]

69.

Wu MY, Ho HN. The role of cytokines in endometriosis. Am J Reprod Immunol. 2003;49:285–96. [DOI] [PubMed]

70.

Gorai I, Ishikawa M, Onose R, Hirahara F, Minaguchi H. Antiendometrial autoantibodies are generated in patients with endometriosis. Am J Reprod Immunol. 1993;29:116–23. [DOI] [PubMed]

71.

Taylor PV, Maloney MD, Campbell JM, Skerrow SM, Nip MM, Parmar R, et al. Autoreactivity in women with endometriosis. Br J Obstet Gynaecol. 1991;98:680–4. [DOI] [PubMed]

72.

Mathur SP. Autoimmunity in endometriosis: relevance to infertility. Am J Reprod Immunol. 2000;44:89–95. [DOI] [PubMed]

73.

Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertil Steril. 2012;97:7–12. [DOI] [PubMed] [PMC]

74.

Ye W, Xie T, Song Y, Zhou L. The role of androgen and its related signals in PCOS. J Cell Mol Med. 2021;25:1825–37. [DOI] [PubMed] [PMC]

75.

Spritzer PM, Barone CR, Oliveira FB. Hirsutism in polycystic ovary syndrome: pathophysiology and management. Curr Pharm Des. 2016;22:5603–13. [DOI] [PubMed]

76.

Keen MA, Shah IH, Sheikh G. Cutaneous manifestations of polycystic ovary syndrome: a cross-sectional clinical study. Indian Dermatol Online J. 2017;8:104–10. [DOI] [PubMed] [PMC]

77.

Burger HG. Androgen production in women. Fertil Steril. 2002;77:S3–5. [DOI] [PubMed]

78.

Schiffer L, Bossey A, Kempegowda P, Taylor AE, Akerman I, Scheel-Toellner D, et al. Peripheral blood mononuclear cells preferentially activate 11-oxygenated androgens. Eur J Endocrinol. 2021;184:353–63. [DOI] [PubMed] [PMC]

79.

Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM, et al. Endocrine aspects of sexual dysfunction in men. J Sex Med. 2004;1:69–81. [DOI] [PubMed]

80.

Davison SL, Bell R. Androgen physiology. Semin Reprod Med. 2006;24:71–7. [DOI] [PubMed]

81.

Carson JA, Manolagas SC. Effects of sex steroids on bones and muscles: similarities, parallels, and putative interactions in health and disease. Bone. 2015;80:67–78. [DOI] [PubMed] [PMC]

82.

Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21:314–28. [DOI] [PubMed]

83.

Cappelletti M, Wallen K. Increasing women’s sexual desire: the comparative effectiveness of estrogens and androgens. Horm Behav. 2016;78:178–93. [DOI] [PubMed] [PMC]

84.

Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab. 2001;86:1318–23. [DOI] [PubMed]

85.

Münzker J, Hofer D, Trummer C, Ulbing M, Harger A, Pieber T, et al. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100:653–60. [DOI] [PubMed]

86.

Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999;13:946–57. [DOI] [PubMed]

87.

Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:5925–33. [DOI] [PubMed]

88.

Wickenheisser JK, Biegler JM, Nelson-Degrave VL, Legro RS, Strauss JF 3rd, McAllister JM. Cholesterol side-chain cleavage gene expression in theca cells: augmented transcriptional regulation and mRNA stability in polycystic ovary syndrome. PLoS One. 2012;7:e48963. [DOI] [PubMed] [PMC]

89.

Lan CW, Chen MJ, Tai KY, Yu DC, Yang YC, Jan PS, et al. Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling. Sci Rep. 2015;5:14994. [DOI] [PubMed] [PMC]

90.

Boyer A, Lapointe E, Zheng X, Cowan RG, Li H, Quirk SM, et al. WNT4 is required for normal ovarian follicle development and female fertility. FASEB J. 2010;24:3010–25. [DOI] [PubMed] [PMC]

91.

Qiu X, Wei Y, Liu C, Ding C, Zhao S. Hyperandrogen enhances apoptosis of human ovarian granulosa cells via up-regulation and demethylation of PDCD4. Gynecol Endocrinol. 2020;36:333–7. [DOI] [PubMed]

92.

Yang JL, Zhang CP, Li L, Huang L, Ji SY, Lu CL, et al. Testosterone induces redistribution of forkhead box-3a and down-regulation of growth and differentiation factor 9 messenger ribonucleic acid expression at early stage of mouse folliculogenesis. Endocrinology. 2010;151:774–82. [DOI] [PubMed]

93.

Azhary JMK, Harada M, Takahashi N, Nose E, Kunitomi C, Koike H, et al. Endoplasmic reticulum stress activated by androgen enhances apoptosis of granulosa cells via induction of death receptor 5 in PCOS. Endocrinology. 2019;160:119–32. [DOI] [PubMed]

94.

Azhary JMK, Harada M, Kunitomi C, Kusamoto A, Takahashi N, Nose E, et al. Androgens increase accumulation of advanced glycation end products in granulosa cells by activating ER stress in PCOS. Endocrinology. 2020;161:bqaa015. [DOI] [PubMed]

95.

Salehi R, Mazier HL, Nivet AL, Reunov AA, Lima P, Wang Q, et al. Ovarian mitochondrial dynamics and cell fate regulation in an androgen-induced rat model of polycystic ovarian syndrome. Sci Rep. 2020;10:1021. [DOI] [PubMed] [PMC]

96.

Chappell NR, Zhou B, Schutt AK, Gibbons WE, Blesson CS. Prenatal androgen induced lean PCOS impairs mitochondria and mRNA profiles in oocytes. Endocr Connect. 2020;9:261–70. [DOI] [PubMed] [PMC]

97.

He Y, Wang CL. Effects of testosterone on PPARgamma and P450arom expression in polycystic ovary syndrome patients and related mechanisms. Eur Rev Med Pharmacol Sci. 2018;22:1549–53. [DOI] [PubMed]

98.

Zhang B, Wang J, Shen S, Liu J, Sun J, Gu T, et al. Association of androgen excess with glucose intolerance in women with polycystic ovary syndrome. Biomed Res Int. 2018;2018:6869705. [DOI] [PubMed] [PMC]

99.

Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214–21. [DOI] [PubMed]

100.

Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:5088–95. [DOI] [PubMed]

101.

Yilmaz SA, Kebapcilar A, Koplay M, Kerimoglu OS, Pekin AT, Gencoglu B, et al. Association of clinical androgen excess with radial artery intima media thickness in women with polycystic ovary syndrome. Gynecol Endocrinol. 2015;31:477–82. [DOI] [PubMed]

102.

Kaiser UB, Jakubowiak A, Steinberger A, Chin WW. Differential effects of gonadotropin-releasing hormone (GnRH) pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro. Endocrinology. 1997;138:1224–31. [DOI] [PubMed]

103.

Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab. 1997;82:3728–33. [DOI] [PubMed]

104.

Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 1994;79:1158–65. [DOI] [PubMed]

105.

Marshall JC, Eagleson CA. Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999;28:295–324. [DOI] [PubMed]

106.

Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2248–56. [DOI] [PubMed]

107.

Almawi WY, Hubail B, Arekat DZ, Al-Farsi SM, Al-Kindi SK, Arekat MR, et al. Leutinizing hormone/choriogonadotropin receptor and follicle stimulating hormone receptor gene variants in polycystic ovary syndrome. J Assist Reprod Genet. 2015;32:607–14. [DOI] [PubMed] [PMC]

108.

Tian Y, Zhao H, Chen H, Peng Y, Cui L, Du Y, et al. Variants in FSHB are associated with polycystic ovary syndrome and luteinizing hormone level in Han Chinese women. J Clin Endocrinol Metab. 2016;101:2178–84. [DOI] [PubMed]

109.

Shi Y, Han T, Cui L, Wu G, Zheng R, Xia M, et al. White blood cell differential counts in patients with polycystic ovary syndrome: a pilot study on Chinese women. Eur J Obstet Gynecol Reprod Biol. 2013;170:162–4. [DOI] [PubMed]

110.

He S, Mao X, Lei H, Dong B, Guo D, Zheng B, et al. Peripheral blood inflammatory-immune cells as a predictor of infertility in women with polycystic ovary syndrome. J Inflamm Res. 2020;13:441–50. [DOI] [PubMed] [PMC]

111.

Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanovà L, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:2–5. [DOI] [PubMed]

112.

Gallinelli A, Ciaccio I, Giannella L, Salvatori M, Marsella T, Volpe A. Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic ovary syndrome. Fertil Steril. 2003;79:1365–72. [DOI] [PubMed]

113.

Rudnicka E, Kunicki M, Suchta K, Machura P, Grymowicz M, Smolarczyk R. Inflammatory markers in women with polycystic ovary syndrome. Biomed Res Int. 2020;2020:4092470. [DOI] [PubMed] [PMC]

114.

Olsen NJ, Kovacs WJ. Effects of androgens on T and B lymphocyte development. Immunol Res. 2001;23:281–8. [DOI] [PubMed]

115.

Wiernik PH. Androgen therapy for acute myeloid and hairy cell leukemia. Curr Treat Options Oncol. 2018;19:4. [DOI] [PubMed]

116.

Morin-Papunen LC, Duleba AJ, Bloigu A, Järvelin MR, Saikku P, Pouta A. Chlamydia antibodies and self-reported symptoms of oligo-amenorrhea and hirsutism: a new etiologic factor in polycystic ovary syndrome? Fertil Steril. 2010;94:1799–804. [DOI] [PubMed]

117.

Marquez-Arrico CF, Silvestre-Rangil J, Gutierrez-Castillo L, Martinez-Herrera M, Silvestre FJ, Rocha M. Association between periodontal diseases and polycystic ovary syndrome: a systematic review. J Clin Med. 2020;9:1586. [DOI] [PubMed] [PMC]

118.

Kyrou I, Karteris E, Robbins T, Chatha K, Drenos F, Randeva HS. Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic. BMC Med. 2020;18:220. [DOI] [PubMed] [PMC]

119.

Huffman AM, Rezq S, Basnet J, Yanes Cardozo LL, Romero DG. SARS-CoV-2 viral entry proteins in hyperandrogenemic female mice: implications for women with PCOS and COVID-19. Int J Mol Sci. 2021;22:4472. [DOI] [PubMed] [PMC]

120.

Özçaka Ö, Buduneli N, Ceyhan BO, Akcali A, Hannah V, Nile C, et al. Is interleukin-17 involved in the interaction between polycystic ovary syndrome and gingival inflammation? J Periodontol. 2013;84:1827–37. [DOI] [PubMed]

121.

Nasri F, Doroudchi M, Namavar Jahromi B, Gharesi-Fard B. T helper cells profile and CD4⁺CD25⁺Foxp3⁺regulatory T cells in polycystic ovary syndrome. Iran J Immunol. 2018;15:175–85. [DOI] [PubMed]

122.

Krishna MB, Joseph A, Subramaniam AG, Gupta A, Pillai SM, Laloraya M. Reduced Tregs in peripheral blood of PCOS patients—a consequence of aberrant Il2 signaling. J Clin Endocrinol Metab. 2015;100:282–92. [DOI] [PubMed]

123.

Li Z, Peng A, Feng Y, Zhang X, Liu F, Chen C, et al. Detection of T lymphocyte subsets and related functional molecules in follicular fluid of patients with polycystic ovary syndrome. Sci Rep. 2019;9:6040. [DOI] [PubMed] [PMC]

124.

Stokkeland LMT, Giskeødegård GF, Ryssdal M, Jarmund AH, Steinkjer B, Madssen TS, et al. Changes in serum cytokines throughout pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2022;107:39–52. [DOI] [PubMed] [PMC]

125.

Zafari Zangeneh F, Naghizadeh MM, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Biomed. 2017;15:375–82. [DOI] [PubMed] [PMC]

126.

Kuang H, Duan Y, Li D, Xu Y, Ai W, Li W, et al. The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome. PLoS One. 2020;15:e0235404. [DOI] [PubMed] [PMC]

127.

Dabravolski SA, Nikiforov NG, Eid AH, Nedosugova LV, Starodubova AV, Popkova TV, et al. Mitochondrial dysfunction and chronic inflammation in polycystic ovary syndrome. Int J Mol Sci. 2021;22:3923. [DOI] [PubMed] [PMC]

128.

Adashi EY, Resnick CE, Packman JN, Hurwitz A, Payne DW. Cytokine-mediated regulation of ovarian function: tumor necrosis factor alpha inhibits gonadotropin-supported progesterone accumulation by differentiating and luteinized murine granulosa cells. Am J Obstet Gynecol. 1990;162:889–96; discussion 896–9. [DOI] [PubMed]

129.

Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod. 1999;61:993–8. [DOI] [PubMed]

130.

Samir M, Glister C, Mattar D, Laird M, Knight PG. Follicular expression of pro-inflammatory cytokines tumour necrosis factor-alpha (TNFalpha), interleukin 6 (IL6) and their receptors in cattle: TNFalpha, IL6 and macrophages suppress thecal androgen production in vitro. Reproduction. 2017;154:35–49. [DOI] [PubMed]

131.

Gao L, Gu Y, Yin X. High serum tumor necrosis factor-alpha levels in women with polycystic ovary syndrome: a meta-analysis. PLoS One. 2016;11:e0164021. [DOI] [PubMed] [PMC]

132.

Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665–8. [DOI] [PubMed]

133.

Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996;97:1111–6. [DOI] [PubMed] [PMC]

134.

Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15. [DOI] [PubMed] [PMC]

135.

Kaipia A, Chun SY, Eisenhauer K, Hsueh AJ. Tumor necrosis factor-alpha and its second messenger, ceramide, stimulate apoptosis in cultured ovarian follicles. Endocrinology. 1996;137:4864–70. [DOI] [PubMed]

136.

Figueroa F, Davicino R, Micalizzi B, Oliveros L, Forneris M. Macrophage secretions modulate the steroidogenesis of polycystic ovary in rats: effect of testosterone on macrophage pro-inflammatory cytokines. Life Sci. 2012;90:733–9. [DOI] [PubMed]

137.

Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker AT, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol. 2003;101:1177–82. [DOI] [PubMed]

138.

Roby KF, Terranova PF. Effects of tumor necrosis factor-alpha in vitro on steroidogenesis of healthy and atretic follicles of the rat: theca as a target. Endocrinology. 1990;126:2711–8. [DOI] [PubMed]

139.

Paolisso G, Rizzo MR, Mazziotti G, Tagliamonte MR, Gambardella A, Rotondi M, et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol. 1998;275:E294–9. [DOI] [PubMed]

140.

Lee KS, Joo BS, Na YJ, Yoon MS, Choi OH, Kim WW. Relationships between concentrations of tumor necrosis factor-alpha and nitric oxide in follicular fluid and oocyte quality. J Assist Reprod Genet. 2000;17:222–8. [DOI] [PubMed] [PMC]

141.

Carlberg M, Nejaty J, Fröysa B, Guan Y, Soder O, Bergqvist A. Elevated expression of tumour necrosis factor alpha in cultured granulosa cells from women with endometriosis. Hum Reprod. 2000;15:1250–5. [DOI] [PubMed]

142.

Artimani T, Karimi J, Mehdizadeh M, Yavangi M, Khanlarzadeh E, Ghorbani M, et al. Evaluation of pro-oxidant-antioxidant balance (PAB) and its association with inflammatory cytokines in polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2018;34:148–52. [DOI] [PubMed]

143.

Peng Z, Sun Y, Lv X, Zhang H, Liu C, Dai S. Interleukin-6 levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. PLoS One. 2016;11:e0148531. [DOI] [PubMed] [PMC]

144.

Päth G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab. 1997;82:2343–9. [DOI] [PubMed]

145.

González F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism. 2009;58:954–62. [DOI] [PubMed] [PMC]

146.

González F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1508–12. [DOI] [PubMed]

147.

González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:336–40. [DOI] [PubMed]

148.

Khashchenko E, Vysokikh M, Uvarova E, Krechetova L, Vtorushina V, Ivanets T, et al. Activation of systemic inflammation and oxidative stress in adolescent girls with polycystic ovary syndrome in combination with metabolic disorders and excessive body weight. J Clin Med. 2020;9:1399. [DOI] [PubMed] [PMC]

149.

Phelan N, O’Connor A, Kyaw Tun T, Correia N, Boran G, Roche HM, et al. Leucocytosis in women with polycystic ovary syndrome (PCOS) is incompletely explained by obesity and insulin resistance. Clin Endocrinol (Oxf). 2013;78:107–13. [DOI] [PubMed]

150.

González F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77:300–5. [DOI] [PubMed] [PMC]

151.

Fox CW, Zhang L, Moeller BC, Garzo VG, Chang RJ, Duleba AJ. Ibuprofen inhibits key genes involved in androgen production in theca-interstitial cells. F S Sci. 2021;2:230–6. [DOI] [PubMed] [PMC]

152.

Fox CW, Zhang L, Sohni A, Doblado M, Wilkinson MF, Chang RJ, et al. Inflammatory stimuli trigger increased androgen production and shifts in gene expression in theca-interstitial cells. Endocrinology. 2019;160:2946–58. [DOI] [PubMed] [PMC]

153.

Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149:R219–27. [DOI] [PubMed]

154.

Barber TM, Franks S. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol. 2013;373:68–76. [DOI] [PubMed]

155.

Blüher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 2009;117:241–50. [DOI] [PubMed]

156.

Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol. 2012;13:707–12. [DOI] [PubMed]

157.

Wensveen FM, Valentić S, Šestan M, Wensveen TT, Polić B. Interactions between adipose tissue and the immune system in health and malnutrition. Semin Immunol. 2015;27:322–33. [DOI] [PubMed]

158.

Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. Adv Nutr. 2016;7:66–75. [DOI] [PubMed] [PMC]

159.

Chan PC, Hsieh PS. The role of adipocyte hypertrophy and hypoxia in the development of obesity-associated adipose tissue inflammation and insulin resistance. In: Gordeladze J, editor. Adiposity—omics and molecular understanding. London: IntechOpen; 2017. pp. 127–41. [DOI]

160.

González F, Kirwan JP, Rote NS, Minium J, O’Leary VB. Glucose and lipopolysaccharide regulate proatherogenic cytokine release from mononuclear cells in polycystic ovary syndrome. J Reprod Immunol. 2014;103:38–44. [DOI] [PubMed] [PMC]

161.

Cortón M, Botella-Carretero JI, Benguría A, Villuendas G, Zaballos A, San Millán JL, et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:328–37. [DOI] [PubMed]

162.

Barbosa-Desongles A, Hernandez C, Simó R, Selva DM. Testosterone induces cell proliferation and cell cycle gene overexpression in human visceral preadipocytes. Am J Physiol Cell Physiol. 2013;305:C355–9. [DOI] [PubMed]

163.

Juan CC, Chen KH, Chen CW, Ho CH, Wang PH, Chen HS, et al. Increased regulated on activation, normal T-cell expressed and secreted levels and cysteine-cysteine chemokine receptor 5 upregulation in omental adipose tissue and peripheral blood mononuclear cells are associated with testosterone level and insulin resistance in polycystic ovary syndrome. Fertil Steril. 2021;116:1139–46. [DOI] [PubMed]

164.

Trujillo ME, Scherer PE. Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167–75. [DOI] [PubMed]

165.

Richards JS, Liu Z, Kawai T, Tabata K, Watanabe H, Suresh D, et al. Adiponectin and its receptors modulate granulosa cell and cumulus cell functions, fertility, and early embryo development in the mouse and human. Fertil Steril. 2012;98:471–9.e1. [DOI] [PubMed] [PMC]

166.

Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome. Diabetologia. 2006;49:2723–8. [DOI] [PubMed]

167.

Shorakae S, Ranasinha S, Abell S, Lambert G, Lambert E, de Courten B, et al. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin Endocrinol (Oxf). 2018;89:628–33. [DOI] [PubMed]

168.

Comim FV, Hardy K, Franks S. Adiponectin and its receptors in the ovary: further evidence for a link between obesity and hyperandrogenism in polycystic ovary syndrome. PLoS One. 2013;8:e80416. [DOI] [PubMed] [PMC]

169.

Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012;76:119–25. [DOI] [PubMed]

170.

Panidis D, Farmakiotis D, Rousso D, Katsikis I, Delkos D, Piouka A, et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med. 2008;19:406–12. [DOI] [PubMed]

171.

Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod. 2007;22:1824–9. [DOI] [PubMed]

172.

Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012;165:622–32. [DOI] [PubMed] [PMC]

173.

Munir I, Yen HW, Baruth T, Tarkowski R, Azziz R, Magoffin DA, et al. Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4852–7. [DOI] [PubMed]

174.

Seow KM, Juan CC, Wu LY, Hsu YP, Yang WM, Tsai YL, et al. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod. 2004;19:48–53. [DOI] [PubMed]

175.

Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and obesity: role and clinical implication. Front Endocrinol (Lausanne). 2021;12:585887. [DOI] [PubMed] [PMC]

176.

Shimizu H, Shimomura Y, Nakanishi Y, Futawatari T, Ohtani K, Sato N, et al. Estrogen increases in vivo leptin production in rats and human subjects. J Endocrinol. 1997;154:285–92. [DOI] [PubMed]

177.

Cakal E, Ustun Y, Engin-Ustun Y, Ozkaya M, Kilinç M. Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome. Gynecol Endocrinol. 2011;27:491–5. [DOI] [PubMed]

178.

Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes. 2008;57:1501–7. [DOI] [PubMed]

179.

Franik G, Plinta R, Madej P, Owczarek A, Bozentowicz-Wikarek M, Chudek J, et al. Circulating vaspin levels and nutritional status and insulin resistance in polycystic ovary syndrome. Ginekol Pol. 2020;91:251–5. [DOI] [PubMed]

180.

Guvenc Y, Var A, Goker A, Kuscu NK. Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome. J Int Med Res. 2016;44:796–805. [DOI] [PubMed] [PMC]

181.

Bongrani A, Mellouk N, Ramé C, Cornuau M, Guerif F, Froment P, et al. Vaspin, a novel adipokine in woman granulosa cells physiology and PCOS pathogenesis? J Endocrinol. 2021;249:57–70. [DOI] [PubMed]

182.

Petríková J, Lazúrová I, Yehuda S. Polycystic ovary syndrome and autoimmunity. Eur J Intern Med. 2010;21:369–71. [DOI] [PubMed]

183.

Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95:1048–58.e1–2. [DOI] [PubMed] [PMC]

184.

Gleicher N, Barad DH. Gender as risk factor for autoimmune diseases. J Autoimmun. 2007;28:1–6. [DOI] [PubMed]

185.

Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol. 2003;38:13–22. [DOI] [PubMed]

186.

Lahita RG. Gender disparity in systemic lupus erythematosus, thoughts after the 8th International Congress on Systemic Lupus Erythematosus, Shanghai, China, 2007. J Clin Rheumatol. 2008;14:185–7. [DOI] [PubMed]

187.

Rovenský J, Imrich R, Lazúrová I, Payer J. Rheumatic diseases and Klinefelter’s syndrome. Ann N Y Acad Sci. 2010;1193:1–9. [DOI] [PubMed]

188.

Grimaldi CM, Michael DJ, Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol. 2001;167:1886–90. [DOI] [PubMed]

189.

Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol. 2003;176:293–304. [DOI] [PubMed]

190.

Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol. 1999;103:282–8. [DOI] [PubMed]

191.

Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521–74. [DOI] [PubMed]

192.

Tai P, Wang J, Jin H, Song X, Yan J, Kang Y, et al. Induction of regulatory T cells by physiological level estrogen. J Cell Physiol. 2008;214:456–64. [DOI] [PubMed]

193.

Arruvito L, Sanz M, Banham AH, Fainboim L. Expansion of CD4⁺CD25⁺ and FOXP3⁺ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol. 2007;178:2572–8. [DOI] [PubMed]

194.

Chapman JC, Min SH, Freeh SM, Michael SD. The estrogen-injected female mouse: new insight into the etiology of PCOS. Reprod Biol Endocrinol. 2009;7:47. [DOI] [PubMed] [PMC]

195.

Baig M, Rehman R, Tariq S, Fatima SS. Serum leptin levels in polycystic ovary syndrome and its relationship with metabolic and hormonal profile in pakistani females. Int J Endocrinol. 2014;2014:132908. [DOI] [PubMed] [PMC]